A breakthrough has been made in the fight against the dreaded Ebola virus which has taken thousands of lives in recent years.
Scientists working on curing the disease in the Democratic Republic of Congo have two out of four drugs being tested on infected patients, showing ‘90% survival rate’, the first effective treatment for the disease.
Both drugs, REGN-EB3 (a cocktail of three antibodies) and mAB114 (monoclonal antibody) were developed using antibodies harvested from survivors of Ebola. They were derived in part from the original research of an African Dr Jean-Jacques Muyembe who has been fighting Ebola since 1976.
Two people cured of Ebola using two experimental drugs have been released from a treatment centre in the eastern Democratic Republic of Congo and reunited with their families.
According to BBC reports, early diagnosis and treatment, however, more than 90% of infected people can survive if they are given REGN-EB3 and mAb114, researchers say.
Trials were coordinated by the World Health Organization and its panel has now recommended the treatments for use by all patients.
The recent study began on November 20, 2018, in the Democratic Republic of the Congo (DRC) as part of the emergency response to an ongoing Ebola outbreak in the North Kivu and Ituri Provinces.
DRC’s Ebola outbreak has killed at least 1,800 people since Aug. 2018 and it’s the 2nd-largest Ebola outbreak in world history.